Sensorineural hearing loss is prevalent in patients receiving cisplatin therapy. Tetramethylpyrazine (Tet) and tanshinone iia (Tan iia) have protective roles against hearing impairment or ototoxicity. The present study aimed to investigate the molecular mechanisms underlying cisplatin-induced ototoxicity and the protective effect of Tet and Tan iia against it. House ear institute-organ of corti 1 auditory cells were treated with titrating doses of Tan iia, Tet, and cisplatin. in a cell viability assay, cisplatin, Tan iia and Tet had ic 50 values of 42.89 µM, 151.80 and 1.04x10 3 mg/l, respectively. Tan iia augmented cisplatin-induced cytotoxicity. However, Tet concentrations <75 mg/l attenuated cisplatin-induced cytotoxicity and apoptosis. Moreover, rna sequencing analysis was carried out on auditory cells treated for 30 h with 30 µM cisplatin alone for 48 h or combined with 37.5 mg/l Tet for 30 h. differentially expressed genes (deGs) induced in these conditions were identified and examined using Gene Ontology and Kyoto encyclopedia of Genes and Genomes pathway analysis. cisplatin increased the expression of genes related to the p53 and Foxo pathways, such as Fas, p21/cdKn1a, and Bcl-2 binding component 3, but decreased the expression of insulin-like growth factor 1 (iGF1), as well as genes in the histone (Hist)1 and Hist2 clusters. Treatment with Tet downregulated FoXo3 and Bcl-2 binding component 3, and increased the expression of iGF1. Moreover, Tet upregulated genes associated with Wnt signaling, but not p53-related genes. Thus, the otoprotective properties of Tet might be mediated by activation of Wnt and iGF1 signaling, and inhibition of Foxo signaling.